Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Warrant extension

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Jun 15, 2022 7:56am

154 Views

Post# 34757378

RE:Warrant extension

Doccole wrote:
What will this mean for the stock price?

What / if any significance does this news bring?

thanks for thoughts!

Renegotiated pricing on the warrant in order to still be able to bring in some cash before 2024. Probably wise to have that stream of cash available as ATE will be burning through cash.

The potential expiration of of the June warrants wasn't doing anything to prop up the share price so I wouldn't think it will have any effect the other way either. Guessing it's neutral.

Will there be panic because of the general market condition or because people don't get it? Can't say either way.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario